The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Cytokines in pancreatic carcinoma: Correlation with phenotypic characteristics and prognosis
Abstract
BACKGROUND: Cytokines have been implicated in diverse processes that are relevant to pancreatic carcinoma, including cachexia, asthenia, and tumor growth. The objective of this study was to examine the association between serum levels of proinflammatory and antiinflammatory or angiogenic cytokines and the outcomes of patients with pancreatic carcinoma. METHODS: Serum cytokine levels were measured by enzyme‐linked immunosorbent assay from 51 patients with pancreatic carcinoma and from 48–62 healthy volunteers. Cytokine levels were compared with disease manifestations and overall survival. RESULTS: Circulating levels of vascular endothelial growth factor, tumor necrosis factor alpha, interleukin‐1α (IL‐1α), and IL‐1β were not elevated significantly in patients with pancreatic carcinoma, but levels of IL‐6, IL‐8, IL‐10, and IL‐1 receptor antagonist (IL‐1RA) were elevated significantly (P < 0.05). Cytokine levels were dichotomized based on an analysis of null Martingale residuals. Patients who had IL‐6 levels > 5.2 pg/mL or IL‐10 levels > 9.8 pg/mL had significantly worse survival compared with patients who had lower IL‐6 or IL‐10 levels (P < 0.05). IL‐8 levels were not associated with survival differences. Patients who had IL‐1RA levels < 159 pg/mL had significantly worse survival compared with patients who had higher IL‐1RA levels (P < 0.05). Higher IL‐6, IL‐10, and IL‐8 levels were associated with poor performance status and/or weight loss. In multivariate analysis, only T 4 tumors and high IL‐6 levels were selected as independent prognostic factors for poor survival. CONCLUSIONS: Circulating levels of several cytokines were high in patients with pancreatic carcinoma, and their association with weight loss and poor performance status suggested that they may be involved in these disease manifestations. Furthermore, serum cytokine levels, in particular IL‐6, may be a useful prognostic marker. Cancer 2004. © 2004 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases
Barnes, P. J., & Karin, M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704103361506 · Cited by 4,669
Fiorentino, D. F., Bond, M. W., & Mosmann, T. R. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.6.2081 · Cited by 2,733
Interleukin-6 family of cytokines and gp130
Kishimoto, T., Akira, S., Narazaki, M., & Taga, T. (1995) · Blood · doi:10.1182/blood.v86.4.1243.bloodjournal8641243 · Cited by 1,272
Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes
Rousset, F., Garcia, E., Defrance, T., Péronne, C., Vezzio, N., Hsu, D. H., Kastelein, R., Moore, K. W., & Banchereau, J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1890 · Cited by 1,238
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928
The balance between IL-1 and IL-1Ra in disease
Arend, W. P. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00020-5 · Cited by 721
Interleukin-8 and human cancer biology
Xie, K. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00016-8 · Cited by 689
Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
Strassmann, G., Fong, M., Kenney, J. S., & Jacob, C. O. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115767 · Cited by 658
Wang, W., Abbruzzese, J. L., Evans, D. B., Larry, L., Cleary, K. R., & Chiao, P. J. (1999) · PubMed · Cited by 651
Self-citationLy‐1 B (B‐1) cells are the main source of B cell‐derived interleukin 10
O'garra, A., Chang, R., Go, N., Hastings, R., Haughton, G., & Howard, M. (1992) · European Journal of Immunology · doi:10.1002/eji.1830220314 · Cited by 526
Interleukin-6 in human multiple myeloma
Klein, B., Zhang, X., Lu, Z., & Bataille, R. (1995) · Blood · doi:10.1182/blood.v85.4.863.bloodjournal854863 · Cited by 520
Interleukin 10: a novel stimulatory factor for mast cells and their progenitors.
Thompson-Snipes, L., Dhar, V, Bond, M. W., Mosmann, T. R., Moore, K. W., & Rennick, D. M. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.2.507 · Cited by 495
Go, N. F., Castle, B. E., Barrett, R., Kastelein, R., Dang, W., Mosmann, T. R., Moore, K. W., & Howard, M. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.6.1625 · Cited by 475
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
Blay, J., Négrier, S., Combaret, V., Attali, S., Goillot, E., Merrouche, Y., Mercatello, A., Ravault, A., Tourani, J. M., & Jf, M. (1992) · PubMed · Cited by 420
Falconer, J. S., Fearon, K. C. H., Plester, C. E., Ross, J. A., & Carter, D. C. (1994) · Annals of Surgery · doi:10.1097/00000658-199404000-00001 · Cited by 415
Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins
Mackiewicz, A., Schooltink, H., Heinrich, P. C., & Rose-John, S. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.6.2021 · Cited by 370
Serum interleukin‐6 levels reflect the disease status of colorectal cancer
Chung, Y., & Chang, Y. (2003) · Journal of Surgical Oncology · doi:10.1002/jso.10269 · Cited by 353
Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10
O'Garra, A., Stapleton, G., Dhar, V., Pearce, M., Schumacher, J., Rugo, H., Barbls, D., Stall, A., Cupp, J., Moore, K., et al. (1990) · International Immunology · doi:10.1093/intimm/2.9.821 · Cited by 344
Fayad, L., Keating, M. J., Reuben, J. M., O'Brien, S., Lee, B.-N., Lerner, S., & Kurzrock, R. (2001) · Blood · doi:10.1182/blood.v97.1.256 · Cited by 290
Self-citationInterleukin-6: A candidate mediator of human prostate cancer morbidity
Twillie, D. A., Eisenberger, M. A., Carducci, M. A., Hseih, W.-S., Kim, W. Y., & Simons, J. W. (1995) · Urology · doi:10.1016/s0090-4295(99)80034-x · Cited by 286
Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor
Blay, J., Burdin, N., Rousset, F., Lenoir, G., Biron, P., Philip, T., Banchereau, J., & Favrot, M. (1993) · Blood · doi:10.1182/blood.v82.7.2169.2169 · Cited by 249
Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer
Berek, J. S., Chung, C., Kaldi, K., Watson, J. M., Knox, R. M., & Martínez-Maza, O. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)90582-c · Cited by 238
Benjamin, D., Knobloch, T., & Dayton, M. (1992) · Blood · doi:10.1182/blood.v80.5.1289.1289 · Cited by 232
Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies.
Weber, J., Yang, J. C., Topalian, S. L., Parkinson, D. R., Schwartzentruber, D. S., Ettinghausen, S. E., Gunn, H., Mixon, A., Kim, H., & Cole, D. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.499 · Cited by 216
Black, K., Garrett, I. R., & Mundy, G. R. (1991) · Endocrinology · doi:10.1210/endo-128-5-2657 · Cited by 199
Kurzrock, R., Redman, J. R., Cabanillas, F., JONES, D. M., Rothberg, J. M., & Talpaz, M. (1993) · PubMed · Cited by 168
Self-citationDaftarian, P. M., Kumar, A., Kryworuchko, M., & Diaz-Mitoma, F. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.1.12 · Cited by 168
Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma
Seymour, J. F., Talpaz, M., Cabanillas, F., Wetzler, M., & Kurzrock, R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.575 · Cited by 164
Self-citationA possible autocrine role for interleukin-6 in two lymphoma cell lines
Yee, C., Biondi, A., Wang, X., Iscove, N., de Sousa, J., Aarden, L., Wong, G., Clark, S., Messner, H., & Minden, M. (1989) · Blood · doi:10.1182/blood.v74.2.798.798 · Cited by 159
Interleukin-6 is a prognostic factor in multiple myeloma [letter] [see comments]
Ludwig, H., Nachbaur, D., Fritz, E., Krainer, M., & Huber, H. (1991) · Blood · doi:10.1182/blood.v77.12.2794.2794 · Cited by 158
Interleukin 6 gene expression in normal and neoplastic B cells.
Freeman, G. J., Freedman, A. S., Rabinowe, S. N., Segil, J., Horowitz, J. B., Rosen, K., Whitman, J., & Nadler, L. M. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114046 · Cited by 154
Elevated Serum Interleukin-6 Levels in Patients with Pancreatic Cancer
Okada, S., Okusaka, T., Ishii, H., Kyogoku, A., Yoshimori, M., Kajimura, N., Yamaguchi, K., & Kakizoe, T. (1998) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/28.1.12 · Cited by 153
Nachbaur, D., Herold, M., Maneschg, A., & Huber, H. P. (1991) · Annals of Hematology · doi:10.1007/bf01714900 · Cited by 135
Nemunaitis, J. J., Fong, T. C., Shabe, P., Martineau, D., & Ando, D. G. (2001) · Cancer Investigation · doi:10.1081/cnv-100102550 · Cited by 131
Scala, G., Quinto, I., Ruocco, M. R., Arcucci, A., Mallardo, M., Caretto, P., Forni, G., & Venuta, S. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.172.1.61 · Cited by 116
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma
Preti, H. A., Cabanillas, F., Talpaz, M., Tucker, S. L., Seymour, J. F., & Kurzrock, R. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-3-199708010-00002 · Cited by 112
Self-citationInterleukin-6 is pyrogenic but not somnogenic
Opp, M. R., Obál, F., Cady, A. B., Johannsen, L., & Krueger, J. M. (1989) · Physiology & Behavior · doi:10.1016/0031-9384(89)90239-4 · Cited by 112
Interleukin-6 production in posttransplant lymphoproliferative disease.
Tosato, G., Jones, K., Breinig, M. K., McWilliams, H., & McKnight, J. L. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116523 · Cited by 109
Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer
Hatanaka, H., Abe, Y., Kamiya, T., Morino, F., Nagata, J., Tokunaga, T., Oshika, Y., Suemizu, H., Kijima, H., Tsuchida, T., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008375208574 · Cited by 99
Estrov, Z. E., Kurzrock, R., Wetzler, M., Kantarjian, H. M., Blake, M. E., Harris, D., Gutterman, J., & Talpaz, M. (1991) · Blood · doi:10.1182/blood.v78.6.1476.1476 · Cited by 96
Self-citationInterleukin-10 in Non-Hodgkin's Lymphoma
Cortes, J. E., & Kurzrock, R. (1997) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199709051774 · Cited by 92
Self-citationSeymour, J. F., Talpaz, M., Hagemeister, F. B., Cabanillas, F., & Kurzrock, R. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00352-x · Cited by 80
Self-citationEstrov, Z., Kurzrock, R., Estey, E. H., Wetzler, M., Ferrajoli, A., Harris, D., Blake, M. E., Gutterman, J., & Talpaz, M. (1992) · Blood · doi:10.1182/blood.v79.8.1938.1938 · Cited by 76
Self-citationWetzler, M., Kurzrock, R., Estrov, Z. E., Kantarjian, H. M., Gisslinger, H., Underbrink, M., & Talpaz, M. (1994) · Blood · doi:10.1182/blood.v84.9.3142.3142 · Cited by 70
Self-citationLong-Term Consequences of Interleukin-6 Overexpression in Transgenic Mice
Woodroofe, C. P., Müller, W., & Rüther, U. (1992) · DNA and Cell Biology · doi:10.1089/dna.1992.11.587 · Cited by 69
Cortes, J. E., Talpaz, M., Cabanillas, F., Seymour, J., & Kurzrock, R. (1995) · Blood · doi:10.1182/blood.v85.9.2516.bloodjournal8592516 · Cited by 54
Self-citationHigh Serum Interleukin-6 Levels Correlate with a Shorter Failure-Free Survival in Indolent Lymphoma
Fayad, L., Cabanillas, F., Talpaz, M., McLaughlin, P. J., & Kurzrock, R. (1998) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199809057568 · Cited by 50
Self-citationIncreased levels of circulating interleukin‐6 in patients with hodgkin's disease
Gause, A., Scholz, R., Klein, S. C., Jung, W. E., Diehl, V., Tesch, H., Hasenclever, D., & Pfreundschuh, M. (1991) · Hematological Oncology · doi:10.1002/hon.2900090605 · Cited by 32
Cytokine Production by CAPAN-1 and CAPAN-2 Cell Lines
Blanchard, J. A., Barve, S. S., Joshi‐Barve, S., et al. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005573024448 · Cited by 28
Interleukin-6: biologic properties and role in lymphoproliferative disorders
Seymour, J. F., & Kurzrock, R. (1996) · Cancer treatment and research · doi:10.1007/978-1-4613-1261-1_9 · Cited by 13
Self-citation
Cited by
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer
Dhillon, N., Aggarwal, B. B., Newman, R. A., Wolff, R. A., Kunnumakkara, A. B., Abbruzzese, J. L., Ng, C. S., Badmaev, V., & Kurzrock, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0024 · Cited by 1,331
Self-citationMuscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Lesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.009 · Cited by 862
Obesity, Inflammation, and Cancer
Deng, T., Lyon, C. J., Bergin, S., Caligiuri, M. A., & Hsueh, W. A. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044359 · Cited by 794
Metadata
- Authors
- Ebrahimi, B., Tucker, S. L., Li, D., Abbruzzese, J. L., & Kurzrock, R.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-11-03
- Volume
- 101
- Issue
- 12
- Pages
- 2727-2736
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1981000484
- Cited by
- 315
- References
- 50
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.